COVID-19 患者的脂肪酶升高
这项回顾性队列研究纳入美国6个中心71例COVID-19住院患者,评估高脂肪酶血症的发生频率与特征。结果9例(12.1%)出现高脂肪酶血症,2例(2.8%)脂肪酶超过正常上限3倍,无患者发生急性胰腺炎,高脂肪酶血症与不良结局或症状无关。
要点
- 71例COVID-19住院患者中9例(12.1%)出现高脂肪酶血症。
- 2例(2.8%)脂肪酶超过正常上限3倍,无患者发生急性胰腺炎。
- 高脂肪酶血症与不良结局或症状无关。
核心结论
- 部分COVID-19患者可见血清脂肪酶轻度升高,但未观察到临床急性胰腺炎。
研究设计与样本
- 回顾性队列研究,纳入美国6个中心的COVID-19住院患者,共71例。
主要发现
- 71例患者中9例(12.1%)出现高脂肪酶血症。
- 其中2例(2.8%)脂肪酶超过正常上限3倍。
- 无患者发生急性胰腺炎。
- 高脂肪酶血症与不良结局或症状无关。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Although coronavirus disease (COVID-19) has been associated with gastrointestinal manifestations, its effect on the pancreas remains unclear. We aimed to assess the frequency and characteristics of hyperlipasemia in patients with COVID-19. METHODS: A retrospective cohort study of hospitalized patients across 6 US centers with COVID-19. RESULTS: Of 71 patients, 9 (12.1%) developed hyperlipasemia, with 2 (2.8%) greater than 3 times upper limit of normal. No patient developed acute pancreatitis. Hyperlipasemia was not associated with poor outcomes or symptoms. DISCUSSION: Although a mild elevation in serum lipase was observed in some patients with COVID-19, clinical acute pancreatitis was not seen.
引用
- McNabb-Baltar J, Jin DX, Grover AS, et al. Lipase Elevation in Patients With COVID-19. Am J Gastroenterol. 2020. PMID: 32496339. doi:10.14309/ajg.0000000000000732
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。